387 related articles for article (PubMed ID: 22185586)
1. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.
Sofia MJ; Chang W; Furman PA; Mosley RT; Ross BS
J Med Chem; 2012 Mar; 55(6):2481-531. PubMed ID: 22185586
[No Abstract] [Full Text] [Related]
2. Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs.
Madela K; McGuigan C
Future Med Chem; 2012 Apr; 4(5):625-50. PubMed ID: 22458682
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antiviral properties of novel tetracyclic nucleoside inhibitors of hepatitis C NS5B polymerase.
Di Francesco ME; Avolio S; Dessole G; Koch U; Pompei M; Pucci V; Rowley M; Summa V
Nucleosides Nucleotides Nucleic Acids; 2012; 31(8):592-607. PubMed ID: 22908950
[TBL] [Abstract][Full Text] [Related]
4. Preparation and biological evaluation of 1'-cyano-2'-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors.
Mish MR; Cho A; Kirschberg T; Xu J; Zonte CS; Fenaux M; Park Y; Babusis D; Feng JY; Ray AS; Kim CU
Bioorg Med Chem Lett; 2014 Jul; 24(14):3092-5. PubMed ID: 24907145
[TBL] [Abstract][Full Text] [Related]
5. Current perspective of HCV NS5B inhibitors: a review.
Patil VM; Gupta SP; Samanta S; Masand N
Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066
[TBL] [Abstract][Full Text] [Related]
6. Nucleoside analog inhibitors of hepatitis C virus replication.
Carroll SS; Olsen DB
Infect Disord Drug Targets; 2006 Mar; 6(1):17-29. PubMed ID: 16787301
[TBL] [Abstract][Full Text] [Related]
7. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.
Beaulieu PL
Curr Opin Investig Drugs; 2007 Aug; 8(8):614-34. PubMed ID: 17668364
[TBL] [Abstract][Full Text] [Related]
8. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
9. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase.
Brown JA; Thorpe IF
Biochemistry; 2015 Jul; 54(26):4131-41. PubMed ID: 26066778
[TBL] [Abstract][Full Text] [Related]
10. New NS5B polymerase inhibitors for hepatitis C.
Legrand-Abravanel F; Nicot F; Izopet J
Expert Opin Investig Drugs; 2010 Aug; 19(8):963-75. PubMed ID: 20629614
[TBL] [Abstract][Full Text] [Related]
11. The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics.
Beaulieu PL
IDrugs; 2006 Jan; 9(1):39-43. PubMed ID: 16374732
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a 2'-fluoro-2'-C-methyl C-nucleotide HCV polymerase inhibitor and a phosphoramidate prodrug with favorable properties.
Kirschberg TA; Metobo S; Clarke MO; Aktoudianakis V; Babusis D; Barauskas O; Birkus G; Butler T; Byun D; Chin G; Doerffler E; Edwards TE; Fenaux M; Lee R; Lew W; Mish MR; Murakami E; Park Y; Squires NH; Tirunagari N; Wang T; Whitcomb M; Xu J; Yang H; Ye H; Zhang L; Appleby TC; Feng JY; Ray AS; Cho A; Kim CU
Bioorg Med Chem Lett; 2017 Apr; 27(8):1840-1847. PubMed ID: 28274633
[TBL] [Abstract][Full Text] [Related]
13. Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase.
Zheng BZ; D'Andrea SV; Hanumegowda U; Knipe JO; Mosure K; Zhuo X; Lemm JA; Liu M; Rigat KL; Wang YK; Fang H; Poronsky C; Cutrone J; Wu DR; Arunachalam PN; Balapragalathan TJ; Arumugam A; Mathur A; Meanwell NA; Gao M; Roberts SB; Kadow JF
Bioorg Med Chem Lett; 2017 Aug; 27(15):3294-3300. PubMed ID: 28633899
[TBL] [Abstract][Full Text] [Related]
14. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
[TBL] [Abstract][Full Text] [Related]
15. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
[TBL] [Abstract][Full Text] [Related]
16. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase.
Tomei L; Altamura S; Paonessa G; De Francesco R; Migliaccio G
Antivir Chem Chemother; 2005; 16(4):225-45. PubMed ID: 16130521
[TBL] [Abstract][Full Text] [Related]
17. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.
Rawal RK; Katti SB; Kaushik-Basu N; Arora P; Pan Z
Bioorg Med Chem Lett; 2008 Dec; 18(23):6110-4. PubMed ID: 18947995
[TBL] [Abstract][Full Text] [Related]
18. NS5B RNA dependent RNA polymerase inhibitors: the promising approach to treat hepatitis C virus infections.
Deore RR; Chern JW
Curr Med Chem; 2010; 17(32):3806-26. PubMed ID: 20858218
[TBL] [Abstract][Full Text] [Related]
19. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase.
Wu JZ; Yao N; Walker M; Hong Z
Mini Rev Med Chem; 2005 Dec; 5(12):1103-12. PubMed ID: 16375756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
